Template:Androgen/anabolic steroid dosages for breast cancer
From HandWiki
Revision as of 15:18, 25 December 2019 by imported>Jworkorg (1 revision imported)
| Route | Medication | Form | Dosage | Refs |
|---|---|---|---|---|
| Oral | Methyltestosterone | Tablet | 30–200 mg/day | [1][2][3][4] |
| Fluoxymesterone | Tablet | 10–40 mg 3x/day | [1][5][6][7] | |
| Calusterone | Tablet | 40–80 mg 4x/day | [1][7] | |
| Normethandrone | Tablet | 40 mg/day | [2] | |
| Buccal | Methyltestosterone | Tablet | 25–100 mg/day | [4] |
| Injection (IM or SC) | Testosterone propionate | Oil solution | 50–100 mg 3x/week | [1][2][8][6][7] |
| Testosterone enanthate | Oil solution | 200–400 mg 1x/2–4 weeks | [9][10] | |
| Testosterone cypionate | Oil solution | 200–400 mg 1x/2–4 weeks | [10] | |
| Mixed testosterone esters | Oil solution | 250 mg 1x/week | [6] | |
| Methandriol | Aqueous suspension | 100 mg 3x/week | [8] | |
| Androstanolone (DHT) | Aqueous suspension | 300 mg 3x/week | [2][8][11] | |
| Drostanolone propionate | Oil solution | 100 mg 1–3x/week | [1][2][7] | |
| Metenolone enanthate | Oil solution | 400 mg 3x/week | [7] | |
| Nandrolone decanoate | Oil solution | 50–100 mg 1x/1–3 weeks | [12][13][14] | |
| Nandrolone phenylpropionate | Oil solution | 50–100 mg/week | [15][7] | |
| Note: Dosages are not necessarily equivalent. | ||||
Template documentationSee also
- Template:Estrogen dosages for breast cancer
- Template:Estrogen dosages for prostate cancer
- Template:Androgen replacement therapy formulations and dosages used in women
- Template:Clinical dosage ranges of oral and injectable androgens and anabolic steroids
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Aurel Lupulescu (24 October 1990). "Hormones and Hormonotherapy". Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 33–90. ISBN 978-0-8493-5973-6. https://books.google.com/books?id=VddUa-2cp-YC&pg=PA57.
- ↑ 2.0 2.1 2.2 2.3 2.4 Dao, Thomas L. (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA170.
- ↑ https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/083976s031lbl.pdf
- ↑ 4.0 4.1 Manuchair Ebadi (31 October 2007). Desk Reference of Clinical Pharmacology. CRC Press. pp. 434–. ISBN 978-1-4200-4744-8. https://books.google.com/books?id=ihxyHbnj3qYC&pg=PA434.
- ↑ Michael Clinton Perry (2008). The Chemotherapy Source Book. Lippincott Williams & Wilkins. pp. 369–. ISBN 978-0-7817-7328-7. https://books.google.com/books?id=CDADMzS0TKUC&pg=PA369.
- ↑ 6.0 6.1 6.2 G. Martz (13 March 2013). Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms. Springer-Verlag. pp. 39–. ISBN 978-3-642-86282-3. https://books.google.com/books?id=8E-qBgAAQBAJ&pg=PA39.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 Janet Brotherton (1976). Sex Hormone Pharmacology. Academic Press. pp. 437. ISBN 978-0-12-137250-7. https://books.google.com/books?id=zt5sAAAAMAAJ.
- ↑ 8.0 8.1 8.2 Council on Drugs (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients". JAMA 172 (12): 1271–83. doi:10.1001/jama.1960.03020120049010.
- ↑ https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009165s031lbl.pdf
- ↑ 10.0 10.1 American Medical Association. Division of Drugs; American Society for Clinical Pharmacology and Therapeutics (1983). "Androgens and Anabolic Steroids". AMA Drug Evaluations. American Medical Association. pp. 913–930. ISBN 978-0-89970-160-8. https://books.google.com/books?id=tsVKAQAAIAAJ. "TESTOSTERONE CYPIONATE [Andro-Cyp, Depo-Testosterone, T-Ionate-P.A.] TESTOSTERONE ENANTHATE [Andryl, Delatestryl] These long-acting, potent esters of testosterone can maintain the testosterone level within the normal range in males for two to four weeks. [...] For metastatic breast carcinoma in women, 200 to 400 mg every two or more weeks."
- ↑ Segaloff, Albert; Horwitt, Benjamin N.; Cakabasi, Ralph A.; Murison, Path J.; Osser, Joskph V. Scht. (1955). "Hormonal therapy in cancer of the breast.VIII. The effect of dihydrotestosterone (Androstanolone) on clinical course and hormonal excretion". Cancer 8 (1): 82–86. doi:10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R. ISSN 0008-543X.
- ↑ https://web.archive.org/web/20190309024812/https://gp2u.com.au/static/pdf/D/DECA-DURABOLIN-PI.pdf
- ↑ https://web.archive.org/web/20180128030754/http://medsafe.govt.nz/profs/Datasheet/d/Decadurabolininj.pdf
- ↑ Ronald I. Shorr (11 April 2007). Drugs for the Geriatric Patient E-Book. Elsevier Health Sciences. pp. 844–. ISBN 978-1-4377-1035-9. https://books.google.com/books?id=-gmjBQAAQBAJ&pg=PA844.
- ↑ W. Llewellyn McKone (11 November 2013). Osteopathic Athletic Health Care: Principles and practice. Springer. pp. 125–. ISBN 978-1-4899-3067-5. https://books.google.com/books?id=2bkACAAAQBAJ&pg=PA125.
